ArticleFrontiers in transplantation2026
Sex-based survival disparities persist in liver transplantation: MELD 3.0 fails to improve survival for waitlisted women.
Article in Frontiers in transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & aims: As a response to the well-documented disadvantages within the current allocation system, MELD 3.0 emerged on July 15, 2023, to more accurately characterize end-stage liver disease severity across the sexes. While simulation modeling predicted fewer waitlist deaths compared to MELD-Na, there is a lack of empirical data evaluating the efficacy of MELD 3.0 since its implementation. This study aims to conduct a waitlist patient survival study to explore sex- and age-based survival disparities in women and quantify empirical survival differences among waitlisted liver transplant candidates before and after the implementation of MELD 3.0. Methods: A retrospective, cross-sectional patient risk analysis of the Scientific Registry of Transplant Recipients (SRTR) database of liver transplant candidates listed from January 1, 2017, to September 3, 2024. Setting: The United States. Participants: Adult liver transplant candidates on the waitlist ( Exposures: All-cause patient waitlist mortality. Main outcomes and measures: The primary outcome was the persistence of the waitlist survival gap between the sexes before and after the implementation of MELD 3.0. Secondary outcomes included risk-adjusted survival disparities in association with age. Results: Across the two MELD eras, waitlisted females experienced a 16.28% mean increase in the relative 180-day median hazard ratio as compared to males. Patients 65 years and older had a 350% mean increase in their 180-day mortality hazard ratio as compared to patients 18 to 35 years of age. Patients 65 years of age and older with MELD scores greater than 34 experienced a 180-day median survival probability of 65%. Conclusions and relevance: Despite the implementation of MELD 3.0, the waitlist survival gap disadvantaging women persists. The relationships between waitlist survival and patient age and sex are complex and time-dependent. As such, time-dependent survival models along with the addition of patient age and other characteristics could significantly improve patient survival diagnostics and help close the waitlist survival gap between the sexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.